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Interleukin-l0 (IL-10) is known to playa major role in 
suppressing immune and inflammatory responses by 
inhibiting the production of proinflammatory cyto-
kines. Therefore, we hypothesized that IL-1 0 might be 
capable of suppressing allergic contact hypersensitiv-
ity. BALB / c mice were sensitized on the dorsal skin 
with dinitrofluorobenzene and challenged on the ears 
6 d later. The effect ofIL-10 on the elicitation phase of 
contact sensitization was determined by its intrader-
mal injection into the pinnae of the mice at doses of 
0.1-100 ng. At 24 and 48 h after challenge, ear swell-
ing was suppressed in a dose-dependent ma~ner b! i~­
jection ofIL-10 at doses of 10-100 ng. Maxlmalmhl-
I n recent years. it has been found that cytokines l.'lay impor-tant roles in immunologic reactions in the skin [11. Keratino-cytes. which constitute the majority of the cell mass of epidermis, are a potent source for a wide array of proinflam-matory and immunomodulatory cytokmes [2]. Recently, 
several reports have characterized cytokine expression in contact 
hypersensitivity [3,4]. A variety of cytokines, including interleukin-
' 1 (IL-l) [5,6], tumor necrosis factor-a [7,8] , granulocyte 
macrophage-colony-stimulating factor [9], and IL-6.l10,11] may 
play an important role in allergic con~act hyperse~slt1vlty by di-
rectly influencing Langerhans cells, antlgen-present1l1g cells 111 the 
I skin, and lymphocyte participation in the process of the reactIOn. 
IL- I0 (previously termed cytokine synthesis inhibitory factor) 
was described originally as a Th2-derived cytokine that inhibits the 
cytokine release by Thl cells [1 2]. Biologic activities of IL-I0 ill 
vitro clearly show that IL-1 0 inhibits productIOn of cytokines at both 
rnRNA and protein levels by mouse Th 1 clones stimulated by anti-
gen or CD3 antibody in the presence of macrophages (1~, 13]. Fur-
ther investigations have demonstrated that IL-10 ma1l1ta1l1s the via-
bility ofB cells in vitro [14], induces class II major histocompatibility 
complex antigen expression on B cells [15], and enhances mast cell 
proliferation [1 6]. IL-lO also has be~n shown to 1l1111blt strongly 
dendritic cell-induced IFN-y production by a Th 1 cell clone [17], as 
well as the production of IL-1, IL-6, IL-8, tumor necrosis factor 0', 
and granulocyte-macrophage colony-stimulating factor by T cells, 
I monocytes, and activated macrophages [1 8,19]. IL-lO also prevents 
antigen-specific T-cell proliferation by inhibiting monocyte anti· 
Manuscript received March 16, 1994; revised June 9, 1994; accepted for 
I publ ication August 5, 1994. . .. 
Reprint requests to: Dalllel N . Sauder, D,VlSlOn of Dermatology, Sunny-
brook Health Science Centre, 2075 Bayview Ave., A-319, Toronto, On-
tario, Canada M4N 3M5. 
Abbreviation: R T. reverse transcription. 
bition of ear swelling (46.9%) was observed after injec-
tion of 100 ng of IL-10. IL-10-injected ear skins 
showed less inflammatory cell infiltration and de-
creased edema at the dermis compared with controls. 
Because IL-1 0 is known to inhibit Th 1 cytokines such as 
interferon-y, we examined whether the suppressive ef-
fect ofIL-10 on ear swelling was accompanied by IL-
10-induced inhibition ofinterferon-y. We found that 
IL-10 application suppressed interferon-y mRNA up-
regulation in challenged skin. Our results suggest that 
IL-10 significantly modifies the elicitation of allergic 
contact sensitivity reactions. Key words: IFN-y/elicita-
tion phase/DTH.] Invest Dermato1103:811-814, 1994 
gen-presenting capacity through down regulation of major histo-
compatibility complex class II expression [20]. 
Recent evidence showing that murine keratinocytes are capable 
of producing IL-10 mRNA and IL-t 0 protein during the induction 
phase of contact sensitivity [21] suggests that endogenous IL-IO 
may playa role in contact hypersensitivity . In this study, we deter-
mined the effects of exogenous IL-10 on allergic contact hypersen-
sitivity. Our results demonstrated that exogenous IL-lO was effec-
tive in reducing ear swelling, leukocytic infiltration, and IFN-y 
mRNA expression in 2,4-dinitrofluorobenzene (DNFB)-sensitized 
and challenged mice. 
MATERIALS AND METHODS 
Animals Female BALB/c mice were obtained from the Charles River 
Breedin~ Laboratory (Quebec, Canada) and used at 8 to 10 weeks of age. 
Five to SlX nuce were used 111 each experimcntal group. Each expcrimentwas 
repeated at least three times. 
Chemicals Recombinant murine IL-10 protein was purchased from 
Pepro Tech Inc. (Rocky Hill, NJ). The lyophilized powder was reconsti-
tuted 111 phosphate-buffered saline (PBS) to an initial concentration of 100 
Jlg/ml. 
Assay for Contact Hypersensitivity Contact hypcrscnsitivity was in-
duced by the method described previously, with minor modification [22). 
Bnefly, the dorsal sk111 of mlce was shaved and painted with 20 ttl of 0.5% 
DNFB (Sigma. St. Louis, MO) in 4: 1 acetonc: olive oil. Six d later, mice 
were challenged on the dorsal surface of the ears with 10 JlI of 0.2% DNFB. 
Unsellsitized mice also were challenged and used as controls for the irrita-
tion effects of 0.2% DNFB and the local injection procedure. Ear thickness 
was measured with a Peacock spring- loaded micrometer (Ozaki Co., Tokyo, 
J apan) before i,~ ect ion (with IL-1 0 or PBS control) and challenge and at 24 
and 48 h after challenge. The results were expressed as the change (from 
pre-challenge levels) in ear thickness and represent the mean maximal in-
crease within the 48-h observation period. The percent suppression was 
calculated according to the formula 
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(
net ear. swelling in IL-I0 - injected mice) 
% suppression = 1 - X 100. 
net car swelling in PBS-injected mice 
The statistical significance of the differences in mean ear thickness between 
IL-I0 - treated groups and PBS-treated control groups was determined by 
the Student t test. We considered p < 0.05 (two-tailed test) to be significant. 
IL-t 0 Treatment I mmediately before challenge, IL-I0 protein at doses of 
0.1-100 ng in 40 Jil of PBS was injected intradermally into one side of each 
ear of the mouse using a 30-gauge needle under pentobarbital anesthesia (50 
mg/kg intraperitoneally) (Nembutal, Abbott Laboratories, Ontario, Can-
ada). We have shown. previously that up to 40 Jig of rat IgG induced no 
change in ear swelling compared to PBS [22]; therefore, for the present study 
an equal volume of PBS was injected into cars of the control group. 
Histologic Examination Ear samples taken at 48 h after challenge were 
fixed in 10% formalin for routine histologic staining with hematoxylin and 
eosin to examine the density of the dermal infiltration. Hematoxylin and 
eosin-stained sections of control and IL-I0 - treated ear tissues were exam-
ined and compared for histologic changes. The dermal infiltrate was quanti-
tated by examining ten high-power fields with a 100 X oil immersion objec-
tive (net magnification , X 400) in representative areas of each ear. 
RNA Extraction Ear samples taken at 12 and 24 h after the treatment 
were placed in 4 M guanidinium thiocyanate (Sigma, St. Louis, MO) con-
taining 0.72% 2-mercaptoethanol solution (solution D) and stored at 
-70°C. The car specimens were homogenized in solution D, and total 
RNA was extracted using the method of Chomczynski and Sacchi [23] 
(acidic guanidinium thiocyanate-phenol/chloroform extraction) . The 
amount of total RNA was measured by a fluorometer (Model 450, Sequoia-
Turner, CAl. 
Reverse Transcription (RT) - Polymerase Chain Reaction (PCR) 
Synthesis of oligo-dT - primed cDNA was carried out as described previ-
ously [24]. Briefly, 2 Jig of total RNA, 1 Jig of 0Iigo(dT)'2_'8 primers 
(Pharmacia, Dorval, Quebec, Canada), and 500 U of Moloney murine leu-
kemia virus reverse transcriptase (Gibco BRL, Burlington, Onta.rio, Canada) 
were used. The RT reaction was stopped by heating at95 °C for 5 min, and 2 
Jil ofRT reaction mixture was used for each PCR. To carry out the PCR, we 
adopted the method of labeled primer-PCR using y[32P]_ATP (ICN Bio-
medicals Canada Ltd., Quebec, Canada) [24,25]. Primer sets and positive 
cDNA template controls for murine IFN-y and p-actin were obtained from 
Clontech Laboratories (Palo Alto, CAl. The sequences for IFN-y-specific 
primers and p-actin -specific primers were as follows: IFN-y primers, 
upstream,S' -TGCA TCTTGGCTITGCAGCTCTTCCTCATGGC-3'; 
downstream,S' -TGGACCTGTGGGTTGTTGACCTCAAACTTGGC-
3'; p-actin primers, upstream, 5'-GTGGGCCGCTCTAGGCACCA A-3'; 
downstream,S' -CTCTTTGATGTCACGCACGA TTTC-3'. The sample 
mixtures overlaid by 15 Jil of mineral oil were placed in a thermal cycler 
(Perkin-Elmer/Cetus, Notwalk, CT) programmed as follows: denaturation 
at 94 ° C for 1 min, annealing at 65 ° C for IFN-y and 60° C for p-actin for 1 
min, and polymerization at 72°C for 1 min. The linear ranges of signal 
strength for IFN-y and p-actin mRNA were determined by performing 
titrations for target cDNA concentration and cycle number, as described 
previously [24] . 
Analysis ofPCR Products Each PCR product sample was size-fraction-
ated on a 9% sodium dodecylsulfate-polyacrylamide gel. After electrophore-
sis, the gel was exposed to Kodak XAR-5 film, which was developed to 
visualize the PCR products. The relative amount of PCR products was 
determined by laser densitometry (LKB-2222-020, UltroScan XL, Pharma-
cia). For relative semiquantitation, the densitometry values of IFN-y were 
normalized to that of the housekeeping gene, p-actin. Data shown in each 
figure represent a typical result from at least four independent experi-
ments. 
RESULTS 
Ear Swelling Suppression Ear swelling was suppressed signifi-
cantly in ears injected with murine IL-I0 protein at the doses of 10 
and 100 ng compared to the control group (Fig 1). At 48 h after 
challenge, percent suppression of ear swelling in ears injected with 
10 ng of IL-I0 was 33.4 ± 8.1% (p < 0.01), and with 100 ng of 
IL-I0 was 46.9 ± 9.4% (p < 0.005). 
Histologic Findings At 48 h after challenge, an ear sample from 
a sensitized and challenged mouse treated with PBS showed a 
marked cell infiltration, characterized by polymorphonuclear cells 
and lymphoid cells, pronounced edema and vasodilation in the 
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Sensitization Injection Challenge Ear increment (x 10.1 mm) 
0 10 20 
DNFB PBS DNFB 
PBS DNFB 
DNFB 0.1 ng-IL-I0 DNFB 
DNFB 1 ng-IL-I0 DNFB 
DNFB 10 ng-IL-I0 DNFB 
DNFB 100 ng-IL-I0 DNFB 
Figure 1. Reduction of ear swelling by IL-tO. Mice (BALB/c) were 
sensitized by 0.5% DNFB. After 6 d, the ear was injected with 0.1-100 ng 
of IL-I0 or PBS and challenged with 0.2% DNFB. Each experiment was 
repeated at least three times With five to six mice in each group. Data 
represent the mean changes in car thickness ± standard error of the mean at 
48 h after challenge. 
dermis, and exocytosis, spongiosis, and intracellular edema in the 
epidermis (Fig 2A) . Injection of murine IL-I0 before challenge led 
to a significant inhibition in edema and in the number of infiltrated 
cells, not only in the dermis but also in the epidermis (Fig 2B). The 
number of infiltrating cells in the dermis was reduced approxi-
mately 50% by injection of 100 ng IL-I0 (52.8 ± 7.5 cells/high-
power field in control versus 25.0 ± 5.9 in IL-IO-injected ears). 
Suppression of IFN-y mRNA in IL-10-Injected Ears Be-
cause IL-lO is known to inhibit the production of Th 1 cytokines 
such as IFN-y, we examined whether the suppressive effect ofIL-lO 
on ear swelling was accompanied by IL-IO-induced inhibition of 
IFN-y. At various times after IL-I0 treatment and challenge, total 
RNA was extracted from the mOllse ears, and IFN-y mRNA expres- \ 
sion was measured by RT-PCR. 
The dependency of signal intensity on PCR cycle number was 
assessed not only to gain optimal signal strength but also to permit 
semiquantitative analysis. PCR signals for IFN-y and p-actin were 
obtained after 28 and 20 cycles, respectively (Fig 3) . However, we 
selected 32 and 24 cycles for IFN-y and p-actin because these cycle 
numbers were midpoints of their respective linear ranges for amp Ii-
B 
Figure 2. Reduction of inflammatory infiltration by IL-tO. Hema-
toxylin and eosin-stained sections of ears 48 h after DNFB challenge of a 
sensitized mouse given 40 ttl PBS (A) or 100 ng IL-l0 (B) before challenge. 
A, Marked polymorphonuclear cel l infiltration, pronounced edema, and 
vasodilation are observed in the dermis, and exocytosis, spongiosis, and 
intracellular edema are observed in the epidermis. B, Decreased edema and 
polymorphonuclear ce ll infiltration in the dermis and the epidermis. Figures 
show cross sections of the corresponding central areas of the ears. Bar, 50 Jim. 
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Figure 3. Effect of cycle number on signal strength for IFN-y and 
p_actin. Two J-lg of total RNA from control challenged car at 24 h after the 
treatment was reverse-transcribed to eDNA. Two microliters of eDNA was 
amplified with both [np)-labeled 5' and unlabeled 3' primer sets for IFN-y 
and j3-actin, as described in Materials alld Methods. PCR products were ana-
lyzed by electrophoresis and autoradiography. Top, show representative au-
toradiograms of RT-PCR signals for IFN-y (A) and p-actin (B). Bottom, 
shoW densitometric quantification of the autoradiograms for IFN-y and 
p-actin signals. 
lication of 2 pI of cDNA reaction product (Fig 3). These results 
showed that under these conditions, the PCR amplification for both 
products was not saturated. 
Figure 4A shows a representative autoradiogram of RT-PCR 
signals for IFN-y and p-actin. Sizes of both products coincided with 
the predicted bp (365 bp for IFN-y and 540 bp for p-actin). Control 
ear samples showed dramatic upregulation of IFN-y mRNA at 12 
and 24 h after challenge, whereas in IL-I0-treated skin, IFN-y 
mRNA was reduced markedly. Densitometric measurements of 
IFN-y mRNA signals were normalized to those for p-actin. As 
shown in Fig 4B, a twentyfold upregulation was seen in challenged 
control skin but only a two- to threefold increase in IL-lO-treated 
skin at 24 h after challenge. Thus, the expression ofIFN-y transcript 
at 24 h was reduced more than fivefold in IL-l 0 - injected skin 
I compared with challenged control skin. 
DISCUSSION 
The results presented here demonstrate that local application of 
I murine IL-I0 inhibited the elicitation phase of allergic contact hy-
, persensitivity (Fig 1). Histologically, the number of infiltrating 
lymphoid cells at the challenged site was reduced in the IL-I0-
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Figure 4. Reduction ofIFN-y mRNA by !L-to. Total RNA was ex-
tracted from ear specimens at various times after PBS or IL-I0 injection and 
chal lenge. Two J-lg of total RNA was reverse-transcribed to eDNA and 
I amplified with both [32P)-labeled 5' and unlabeled 3' primer sets for IFN-y 
I andj3-actin (PCR cycle numbers were 32 for IFN-yand 24 for p-actin). PCR 
products were analyzed by electrophoresis and autoradiography. A, Repre-
\ sentative autoradiogram of RT-PCR signals for IFN-y (top) and p-actin 
(bo ttom). Lalles 1-3 represent 0 (no treatment), 12, and 24 h after challenge 
treated with PBS. Lalles 4-6 represent 0 (no treatment), 12, and 24 h after 
challenge treated with 100 ng ofIL-tO. B, Densitometric relative quantifi-
cation of the autoradiograms for IFN-y mRNA in IL-l 0 - injected (closed 
/ bars) or PBS-injected (apell bars) ears. The relative amount ofPCR products 
I was determined by scanning of autoradiograms using a laser densitometer. For relative quantification, the densitometric value ofIFN -y was normalized 
to that of p-actin. Levels ofIFN-y mRN A after the treatment were expressed 
relative to those of untreated controls (control = 1.0). The data represent the 
mean ± standard error of the mean of three different experiments run Oll 
triplicate eDNA samples from two different mice in each experiment. 
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treated ear (Fig 2). The elevated IFN-y mRNA levels in the chal-
lenged skin were suppressed by IL-lO treatment (Fig 4). These 
results suggest.t~lat exoge~ous IL-lO can modify the development 
o~ contact senSitivity reactions. This model using injection into the 
pmnae of lruc.e has a m;0or advantage in that intradermal injection 
of IL-lO requtres much lower amounts to block inflammation than 
!ntravenous or intraperitoneal application. In addi tion, local admin-
Istration of IL-l 0 may be advantageous to avoid systemic effects. 
In this study, we selected IFN-y as a monitor ofIL-10 effects on 
cytokine expression because IFN-y expression is associated with the 
func~ional!y distinct T-cell subset, Thl, which is known to pre-
doml~ate m delayed-type hypersensitivity (DTH) reactions [26]. 
Inhibitory effects of IL-I0 on IFN-y production by T cells were 
demonstrated ill lIitro, and it has been shown that the relevant mech-
anism is not due to a direct effect on T cells but rather to inhibition 
of expression of the antigen-presenting cell accessory molecul es, 
which are necessary for fu!' activation of IFN-y production by T 
~ells [13,27]. Our observation that IL-lO-injected ear skin exhib-
Ited lower levels .of IFN-y mRNA than untreated challenged skin 
does not contradl~~ those i,l lIi/m observations, though we cannot 
ne~lect the pOSSIbilIty that IL-I0 may inhibit proliferation and acti-
vatIOn ofTh 1 cells, which simply leads to reduction in their number 
and concomitant reduction in IFN-y production. 
We found that IL-lO - injected ears exhibited a reduction of der-
mal edema and leukocytic cell infiltration. IFN-y has been demon-
strate? to produce some of the feat.ures of D~H [28 - 30], including 
recrUItment of mononuclear cell mfiltrates mto a local inflamma-
tory site [31,32] and increased vascular permeability [33]. Antibody 
to IFN-y was shown to inhibit mouse DTH [34]. IFN-y down 
regulation caused by IL-l 0 may be one of the reasons for the even-
tual reduction of ear swelling on resolution of the DTH response. 
The results presented here are supported by several recent papers. 
Fer~us~n et al [35] demonstrated that locally produced IL-lO after 
an~l~el11C challenge regulates the duration of the contact hypersen-
SIt!~lty :esponse, and also that IL-l 0 injection into the skin before 
a.n~lgemc cha.llenge pre~ents th~ elicitation of contact hypersensi-
tiVity m prevlO~sly senslt!zed mice. The suppressive role of exoge-
nous IL-I0 111 unmunologlC phenomena ill lIillo was also demon-
strated by Schwarz et ai, * who showed that systemic administration 
ofIL-I0 at 24 h before ~hallenge reduces ear swelling using a mur-
I~e contact hypersensItivity modeL Inhibition of sensitization ;'1 
1/ 1110 !las been shown by Enk et al [36]' who demonstrated that local 
appltcatio?- of !L-I0 before sensitization induces antigen-specific 
tolerance 111 mice. 
The exact mech~nisms of IL-I0 inhibitory effects on allergic 
contact hypersenslt!vlty are not yet elucidated completely. Current 
kn~wl~dge favors the Idea that IL-l 0 can inhibit differentiation and 
aCtivatIOn of!h 1. cells, possibly by blocking synthesis of IFN-y or 
by antagol11zmg l.tS actlvat:ng effects on antigen-presenting cells 
r37,38], thus altenng the effector arm of the contact hypersensitiv-
Ity response. 
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